Filtered By:
Specialty: Neurology
Drug: Coumadin
Education: Study

This page shows you your search results in order of date. This is page number 19.

Order by Relevance | Date

Total 277 results found since Jan 2013.

Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation for the Secondary Prevention of Stroke: A Subgroup Analysis of J-ROCKET AF
Conclusions: The safety and efficacy profile of rivaroxaban compared with warfarin was consistent among patients in the primary prevention group and those in the secondary prevention group.
Source: Journal of Stroke and Cerebrovascular Diseases - January 24, 2013 Category: Neurology Authors: Norio Tanahashi, Masatsugu Hori, Masayasu Matsumoto, Shin-ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Hitoshi Ueda, Kazuya Iwamoto, Masahiro Tajiri, J-ROCKET AF Study Investigators Tags: Original Articles Source Type: research

An Emergency Department Intervention to Increase Warfarin Use for Atrial Fibrillation
Conclusions: This practical stroke prevention quality improvement initiative was not associated with an increase in warfarin use among ED patients with AF.
Source: Journal of Stroke and Cerebrovascular Diseases - December 20, 2012 Category: Neurology Authors: Lesli E. Skolarus, Lewis B. Morgenstern, Phillip A. Scott, Lynda D. Lisabeth, Jillian B. Murphy, Erin M. Migda, Devin L. Brown Tags: Original Articles Source Type: research

Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case¿control study
Background: Recombinant factor VIIa (rFVIIa) may be used for rapid hemostasis in life-threatening hemorrhage. In warfarin-associated intracerebral hemorrhage (wICH), FVIIa use is controversial and may carry significant thromboembolic risks. We compared incidence of baseline thromboembolic risk factors and thromboembolism rates in wICH patients treated with additional rFVIIa to those treated with standard therapy of fresh frozen plasma (FFP) and vitamin K alone. Methods: We identified 45 consecutive wICH patients treated with additional rFVIIa over 5-year period, and 34 consecutive wICH patients treated with standard therap...
Source: BMC Neurology - December 15, 2012 Category: Neurology Authors: Chou H-YCai XuemeiKonigsberg GBresette MHenderson VSorond AFeske K Source Type: research

Warfarin versus Aspirin for Prevention of Stroke in Heart Failure: A Meta-analysis of Randomized Controlled Clinical Trials
Conclusions: Compared with aspirin, warfarin reduced the risk of stroke while conferring an increased risk of major hemorrhage. Warfarin does not increase mortality or confer an increased risk of ICH compared with aspirin.
Source: Journal of Stroke and Cerebrovascular Diseases - November 21, 2012 Category: Neurology Authors: Gyanendra Kumar, Munish Kumar Goyal Tags: Original Articles Source Type: research

Rate of Antithrombotic Drug use and Clinical Outcomes According to CHADS2 Scores in Patients With an Initial Cardioembolic Stroke who had Nonvalvular Atrial Fibrillation
This study investigated the relationship between CHADS2 scores and the rate of antithrombotic drug use and clinical outcomes in patients with an initial cardioembolic stroke who had nonvalvular atrial fibrillation (NVAF).Methods: In 234 patients (135 men and 99 women; mean age [±SD] 76 ± 11 years) with initial cardiogenic cerebral embolism with NVAF who were admitted to our hospital between April 2007 and March 2011, the CHADS2 score, use of warfarin, and clinical outcomes were retrospectively investigated.Results: CHADS2 scores were as follows: 0 points, n = 21 (9%); 1 point, n = 72 (31%); 2 points, n = 92 (39%); 3 poin...
Source: Journal of Stroke and Cerebrovascular Diseases - July 23, 2012 Category: Neurology Authors: Ichiro Deguchi, Hiroshi Ogawa, Yasuko Ohe, Manabu Nemoto, Norio Tanahashi Tags: Original Articles Source Type: research

Identifying a High Stroke Risk Subgroup in Individuals with Heart Failure
Conclusions: The combination of previous stroke/TIA and DM increases the incidence of stroke in participants with HF without AF. No analyzed subgroup had a stroke rate high enough to make it likely that the benefits of warfarin would outweigh the risks.
Source: Journal of Stroke and Cerebrovascular Diseases - December 6, 2011 Category: Neurology Authors: Patrick M. Pullicino, Leslie A. McClure, Virginia J. Howard, Virginia G. Wadley, Monika M. Safford, James F. Meschia, Aaron Anderson, George Howard, Elsayed Z. Soliman Tags: Original Articles Source Type: research

Tissue Plasminogen Activator Thrombolytic Therapy for Acute Ischemic Stroke in 4 Hospital Groups in Japan
In October 2005 in Japan, the recombinant tissue plasminogen activator (tPA) alteplase was approved for patients with acute ischemic stroke within 3 hours of onset at a dose of 0.6 mg/kg. The present study was undertaken to assess the safety and efficacy of alteplase in Japan. Between October 2005 and December 2009, a total of 114 consecutive patients admitted to 4 hospitals received intravenous tPA within 3 hours of stroke onset. Clinical backgrounds and outcomes were investigated. The patients were divided into 2 chronological groups: an early group, comprising 45 patients treated between October 2005 and December 2007,...
Source: Journal of Stroke and Cerebrovascular Diseases - October 4, 2011 Category: Neurology Authors: Syoichiro Kono, Kentaro Deguchi, Nobutoshi Morimoto, Tomoko Kurata, Shoko Deguchi, Tohru Yamashita, Yoshio Ikeda, Tohru Matsuura, Hisashi Narai, Nobuhiko Omori, Yasuhiro Manabe, Taijyun Yunoki, Yoshiki Takao, Sanami Kawata, Kenichi Kashihara, Koji Abe Tags: Original Articles Source Type: research